Advertisement

Irish Journal of Medical Science

, Volume 181, Issue 2, pp 211–214 | Cite as

A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series

  • J. NaidooEmail author
  • D. O’Toole
  • M. J. Kennedy
  • J. V. Reynolds
  • M. O’Connor
  • K. O’Byrne
Original Article

Abstract

Background

The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours.

Aim

The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period.

Method

We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient.

Result

The median progression-free survival was 17 months (range 3–48+ months), and overall survival 31 months (range 12–53+ months) with no toxicity related deaths.

Conclusion

FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.

Keywords

Streptozocin Fluorouracil Metastatic Neuroendocrine Tumour 

Notes

Conflict of interest

None.

References

  1. 1.
    Arnold R, Rinke A, Schmidt C, Hofbauer L (2005) Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol 19:649–665PubMedCrossRefGoogle Scholar
  2. 2.
    Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors. Pancreas 39:707–712PubMedCrossRefGoogle Scholar
  3. 3.
    Öberg K (2010) Pancreatic endocrine tumors. Semin Oncol 37:561–594CrossRefGoogle Scholar
  4. 4.
    Basu B, Sirhoni B, Corrie P (2008) Systemic therapy for neuroendocrine tumours of gastroenteropathic origin. Endocr Relat Cancer 17:75–90CrossRefGoogle Scholar
  5. 5.
    Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79:108–118PubMedGoogle Scholar
  6. 6.
    Sun W, Lipsitz S, Catalano P, Maillaird JA, Haller DG (2003) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: ECOG Group Study E1281. J Clin Oncol 23:4897–4904CrossRefGoogle Scholar
  7. 7.
    Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194PubMedCrossRefGoogle Scholar
  8. 8.
    Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1998) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523CrossRefGoogle Scholar
  9. 9.
    Moertel CG, Johnson CM, McKusick MA et al (1994) The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Intern Med 120:302–309PubMedGoogle Scholar
  10. 10.
    La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C (2003) Localisaton of vascular endothelial growth factor and its receptors in digestive endocrine tumours: correlation with microvessel density and clinicopatologic features. Hum Pathol 34:18–27PubMedCrossRefGoogle Scholar
  11. 11.
    Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumours. N Engl J Med 364:501–513PubMedCrossRefGoogle Scholar
  12. 12.
    Phan A, Yao J, Fogelman D. (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide in advanced low-grade neuroendocrine carcinoma J Clin Oncol 28 (absract)Google Scholar
  13. 13.
    Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C (2007) MC044 h, a phase II trial of sorafenib in patients with metastatic neuroendocine tumors: a phase II consortium study [abstract]. ASCO Annual Meeting Proc 25:4505aGoogle Scholar
  14. 14.
    Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumours. N Engl J Med 364:514–523PubMedCrossRefGoogle Scholar
  15. 15.
    O’Donnell PH, Ratatin MJ (2007) Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer 177:177–179CrossRefGoogle Scholar
  16. 16.
    Castellano D (2011) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801)Google Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2011

Authors and Affiliations

  • J. Naidoo
    • 1
    • 2
    Email author
  • D. O’Toole
    • 1
  • M. J. Kennedy
    • 1
  • J. V. Reynolds
    • 1
  • M. O’Connor
    • 2
  • K. O’Byrne
    • 1
  1. 1.Trinity College Dublin, St. James’s HospitalDublin 2Ireland
  2. 2.Waterford Regional HospitalWaterfordIreland

Personalised recommendations